Opened in 2004, the DNDi India office supports the implementation of the various R&D projects. The main focus is on visceral leishmaniasis along with activities in hepatitis C, filariasis, and paediatric HIV. The office also works closely on raising awareness and advocating for increased public responsibility and a more enabling environment for neglected disease R&D.



DNDi India

PHD House, 3rd Floor
4/2 Siri Institutional Area
New Delhi 110016
India
Tel: +91 11 4550 1795

 


  • Retrospective study starts to determine occurrence of PKDL cases in previously treated VL patients
  • DNDi becomes a founding member of newly-launched SPEAK India consortium, funded by the Gates Foundation, for post-elimination agenda for VL in South Asia
  • Trainings in Good Clinical Practice and Good Clinical Laboratory Practice enable clinical staff to apply them in upcoming trials, particularly in Bihar, and to be briefed on specificities of regulations in India
  • Two Indian universities join the Open Synthesis Network, a new open-source drug discovery project 
  • Experts’ meeting with the Indian Council of Medical Research defines the most pressing medical needs and R&D gaps in drug-resistant infections in India